While the first approved single-chain variable fragment (scFv) bispecific T cell engager, blinatumomab, has demonstrated substantial clinical efficacy for the treatment of CD19+ B cell leukemia/lymphoma (22, 23), the clinical benefit of BiMAb targeting TAAs in carcinomas is controversially discussed (24, 25). The gene discussed is CD19; the disease is carcinoma.